Advertisement Axial Biotech names new vice president of strategic initiatives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Axial Biotech names new vice president of strategic initiatives

Axial Biotech, a developer of molecular diagnostic and motion preserving technologies, has appointed Joe Ross as its new vice president of strategic initiatives.

In this new role, Mr Ross will oversee Axial Biotech’s global efforts to identify, evaluate, and pursue new diagnostic opportunities and will help to coordinate the company’s long-term business strategy, solicit investment backing, and expand key development partnerships.

Prior to his most recent position as vice president of global marketing for Stryker Biotech, Mr Ross has worked 11 years with the DePuy Spine division of Johnson and Johnson in roles of increasing responsibility including worldwide vice president for new business development. Mr Ross is a graduate of the University of Notre Dame and Troy State University

John Climaco, president and CEO of Axial Biotech, said: “As we prepare for the commercial introduction of our DNA based prognostic test for adolescent idiopathic scoliosis with our partners at DePuy Spine, we look forward to building on our successful research, and developing additional diagnostic tools to meet the clinical needs of today, and those anticipated in the future.

“Mr Ross is uniquely qualified to drive this effort given his vast industry knowledge and experience, and successful track record of working closely with physician thought leaders to develop innovative clinical solutions.”